Physician profile
Randall Rigdon
NPI 1396791455
$2,660.00
in general payments reported to CMS, 2019-2025
34 companies · $1,560 in 2025
The $1,560 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.88 · 2020: $24.07 · 2021: $161 · 2022: $345 · 2023: $220 · 2024: $250 · 2025: $1,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,029.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $619.81 | 2021-2025 | Viberzi, Ubrelvy, Qulipta |
| Amgen INC. | $208.83 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Glaxosmithkline, LLC. | $193.61 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $181.43 | 2025 | Caplyta |
| Exact Sciences Corporation | $164.86 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $142.85 | 2024-2025 | Voquezna |
| Pfizer INC. | $119.01 | 2022-2025 | |
| Novo Nordisk INC | $107.32 | 2024-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $105.78 | 2025 | Freestyle Libre 3, Aveir |
| Wright Medical Technology, INC. | $99.88 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.91 | 2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $83.61 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $58.22 | 2021-2022 | |
| Astellas Pharma US INC | $52.33 | 2025 | Veozah |
| Amneal Pharmaceuticals LLC | $51.97 | 2022-2025 | Unithroid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $30.55 | 2025 | Fanapt |
| Corcept Therapeutics | $26.54 | 2025 | Korlym |
| Lundbeck LLC | $24.60 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $24.09 | 2022 | |
| Allergan, INC. | $24.07 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.27 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $21.51 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.51 | 2025 | Jardiance |
| Sunovion Pharmaceuticals INC. | $20.23 | 2021 | |
| Lilly USA, LLC | $19.02 | 2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $18.72 | 2025 | Watchman Flx |
| Tolmar, INC. | $18.25 | 2025 | Jatenzo |
| Almatica Pharma LLC | $17.31 | 2025 | Teriparatide |
| Nestle Healthcare Nutrition INC. | $16.64 | 2022 | |
| Verity Pharmaceuticals INC. | $16.24 | 2025 | Tlando |
| Kowa Pharmaceuticals America, INC. | $15.21 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $13.51 | 2025 | Airsupra |
| E.R. Squibb & Sons, L.L.C. | $13.40 | 2024 | Eliquis |
| Sanofi-Aventis U.S. LLC | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Rigdon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.